GlassScriptPhysician profile
Adam Skye Blank
NPI 1710564919
$2,602.19
in general payments reported to CMS, 2019-2025
23 companies · $2,074 in 2025
The $2,074 reported for 2025 was more than what 94% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $529 · 2025: $2,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $625.19 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $311.64 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $245.55 | 2024-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $198.15 | 2024-2025 | |
| Novo Nordisk INC | $181.88 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $142.31 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $136.45 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $122.41 | 2025 | Gemtesa |
| Pfizer INC. | $88.03 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $84.28 | 2025 | |
| Exact Sciences Corporation | $78.09 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $49.86 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $43.91 | 2025 | Zenpep |
| Abiomed | $41.37 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.14 | 2024-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $37.71 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.81 | 2024-2025 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $28.91 | 2024 | Oxlumo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.46 | 2025 | Jardiance |
| Edwards Lifesciences Corporation | $25.60 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Agios Pharmaceuticals, INC. | $21.63 | 2025 | Pyrukynd |
| Ascensia Diabetes Care US INC. | $20.25 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $16.56 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.